Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF

Table 5 Significant correlations between TFPI single nucleotide polymorphisms (SNPs) and total TFPI protein levels in plasma

Protein	SNP	Region	Alleles ^a	Minor allele frequency	Beta	r	P	False discovery rate
Total TFPI	rs8176541^b	Intronic	G:A	0.283	15.64	0.571	7.69 × 10⁻¹⁴	1.08 × 10⁻¹²
Total TFPI	rs3213739^b	Intronic	G:T	0.417	11.35	0.488	5.38 × 10⁻¹⁰	3.77 × 10⁻⁹
Total TFPI	rs8176479^b	Intronic	C:A	0.238	12.22	0.480	1.20 × 10⁻⁹	5.62 × 10⁻⁹
Total TFPI	rs2192824^b	Intronic	C:T	0.490	−9.88	−0.404	3.81 × 10⁻⁷	1.07 × 10⁶
Total TFPI	rs2192825^b	Intronic	T:C	0.466	−7.55	−0.301	2.40 × 10⁻⁴	5.30 × 10⁻⁴
Total TFPI	rs16829088^b	Intronic	G:A	0.250	11.23	0.424	1.00 × 10⁻⁷	3.51 × 10⁻⁷
Total TFPI	rs7594359^b	Intronic	C:T	0.483	−6.90	−0.275	6.90 × 10⁻⁴	0.001
Total TFPI	rs10153820^b	Near 5UTR	G:A	0.125	−7.79	−0.215	0.009	0.016

^aMajor:minor. ^bSNPs representing a haplotype effect for total tissue factor pathway inhibitor (TFPI). Alleles for the positive DNA strand (UCSC annotated) are shown.